未登录

E

Erin J. Stringfellow

MGH Institute for Technology Assessment

H指数:18

被引数:1,600

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prescription Depressant-Involved Overdose Mortality in Massachusetts (2000-2023): A Cohort Study

Journal of General Internal Medicine

IF4.2

2026-01-290

PRE

Substances in Fentanyl Samples in the U.S. Illicit Drug Supply: A Decade of Trends and Regional Variations Using Serial Cross-Sectional Analysis

美国非法药物供应中芬太尼样本的物质：一项使用连续横断面分析的十年趋势和区域差异研究

Drug and Alcohol Dependence

IF3.6

2025-11-070

PRE

The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021

IF5.3

2025-02-240

PRE

Trends and Factors Associated With Opioid and Benzodiazepine Co-Prescription Among Individuals With a History of Opioid Use Disorder in the United States

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2025-02-010

PRE

Uncovering Patterns in Overdose Deaths: An Analysis of Spike Identification in Fatal Drug Overdose Data in Massachusetts, 2017-2023

PUBLIC HEALTH REPORTS

IF2.5

2024-12-240

PRE

Temporal and spatial trends of fentanyl co-occurrence in the illicit drug supply in the United States: a serial cross-sectional analysis

LANCET REGIONAL HEALTH-AMERICAS

IF7.6

2024-11-010

OAAI

Improving Estimates of the Prevalence of Opioid Use Disorder in the United States: Revising Keyes et al

JOURNAL OF ADDICTION MEDICINE

IF3.2

2024-09-021

PRE

State Mandates On Naloxone Coprescribing Associated With Short-Term Increase In Naloxone Codispensing

IF8.1

2024-09-010

PRE

The Impact of CDC's Opioid Prescribing Guideline on Racial Disparities in Discontinuation of Opioid Treatment in the United States

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2024-07-010

PRE

The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States

美国接受丁丙诺啡治疗阿片类药物使用障碍的纵向趋势与丁丙诺啡放弃的提供者之间的关联

IF5.3

2023-07-113

PRE

Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids

JAMA HEALTH FORUM

IF11.3

2023-05-196

OAAI

Enumerating contributions of fentanyls and other factors to the unprecedented 2020 rise in opioid overdose deaths: model-based analysis

IF3.8

2023-03-035

OAAI

Long-Term Effects of Increasing Buprenorphine Treatment Seeking, Duration, and Capacity on Opioid Overdose Fatalities: A Model-based Analysis

JOURNAL OF ADDICTION MEDICINE

IF3.2

2023-02-288

OA

Impact of Alternative Ways to Operationalize Buprenorphine Treatment Duration on Understanding Continuity of Care for Opioid Use Disorder

INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION

IF2.5

2022-12-1613

PRE

Impacts of alcohol and opioid polysubstance use on road safety: Systematic review

ACCIDENT ANALYSIS AND PREVENTION

IF6.2

2022-08-018

PRE

Evaluating disparities in prescribing of naloxone after emergency department treatment of opioid overdose

JOURNAL OF SUBSTANCE ABUSE TREATMENT

IF4

2022-08-0110

OAAI

Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis

SCIENCE ADVANCES

IF12.5

2022-06-2435

OAAI

Modeling the evolution of the US opioid crisis for national policy development

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2022-05-3147

OAAI

Opioid overdose decedent characteristics during COVID-19

ANNALS OF MEDICINE

IF4.3

2022-04-2536

OAAI

Economic Evaluation in Opioid Modeling: Systematic Review

阿片类药物建模的经济评价: 系统综述

VALUE IN HEALTH

IF6

2021-02-0116

OAAI